Fallopian Tube Neoplasms: all 734 studies

Page 3 of 8. Open to participants first (128), then studies with results posted, then the rest; newest registration first within each.

• Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT02498600Phase 2Results posted
• Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT02446600Phase 3Results posted
• MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal CancerTerminatedNCT02364713Phase 2Results posted
• Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian CancerActive, not recruitingNCT02345265Phase 2Results posted
• Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT02312245Phase 2Results posted
• Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal CancerCompletedNCT02311907Phase 3Results posted
• Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube CancerTerminatedNCT02278783Phase 2Results posted
• TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid TumorsActive, not recruitingNCT02142803Phase 1Results posted
• Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02122185Phase 2Results posted
• Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT02101775Phase 2Results posted
• MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube CancerActive, not recruitingNCT02068794Phase 1/2Results posted
• GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian CancerTerminatedNCT02012192Phase 1/2Results posted
• Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior TherapiesCompletedNCT01974765Phase 2Results posted
• Tivozanib As Maintenance Therapy In GYNTerminatedNCT01972516Phase 2Results posted
• Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)CompletedNCT01968213Phase 3Results posted
• Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT01962948Phase 1/2Results posted
• A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)CompletedNCT01891344Phase 2Results posted
• Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal CancerCompletedNCT01853644Phase 2Results posted
• A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerTerminatedNCT01849874Phase 3Results posted
• A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT01846611Phase 3Results posted
• A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian CancerTerminatedNCT01773889Phase 2Results posted
• Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT01767675Phase 2Results posted
• Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal CancerTerminatedNCT01744821Not applicableResults posted
• Accelerating Gastrointestinal RecoveryCompletedNCT01704651Phase 3Results posted
• Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal CancerTerminatedNCT01681368Phase 2Results posted
• BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian CancerCompletedNCT01669798Phase 2Results posted
• VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CancerCompletedNCT01666444Phase 2Results posted
• A Study LY2228820 for Recurrent Ovarian CancerCompletedNCT01663857Phase 1/2Results posted
• A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube CancersTerminatedNCT01659554Phase 2Results posted
• A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian CancerCompletedNCT01610206Phase 2Results posted
• A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)CompletedNCT01482715Phase 1/2Results posted
• A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian CancersCompletedNCT01447706Phase 2Results posted
• BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal CancerCompletedNCT01314105Phase 1Results posted
• Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal CancerCompletedNCT01313078Phase 2Results posted
• A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal CancerTerminatedNCT01312389Phase 1/2Results posted
• Phase II ABT-888 With CyclophosphamideCompletedNCT01306032Phase 2Results posted
• Panitumumab and Gemcitabine in Relapsed Ovarian CancerTerminatedNCT01296035Phase 2Results posted
• Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian CancerTerminatedNCT01275664Not applicableResults posted
• Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal CancerCompletedNCT01248962Phase 2Results posted
• Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With BevacizumabCompletedNCT01223235Not applicableResults posted
• Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary OvarianCompletedNCT01219777Phase 1Results posted
• A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast CancersCompletedNCT01209195Phase 1Results posted
• SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or CarboplatinTerminatedNCT01200797Phase 2Results posted
• Saracatinib and Paclitaxel in Platinum-resistant Ovarian CancerCompletedNCT01196741Phase 2/3Results posted
• Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal CancerCompletedNCT01188876Phase 1/2Results posted
• RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT01175343Phase 2Results posted
• Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerActive, not recruitingNCT01167712Phase 3Results posted
• Neoadjuvant Therapy for Ovarian CancerCompletedNCT01146795Phase 2Results posted
• WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian CancerTerminatedNCT01144442Not applicableResults posted
• Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube CancerTerminatedNCT01137071Phase 2Results posted
• Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast CancerActive, not recruitingNCT01116648Phase 1/2Results posted
• Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast CancerCompletedNCT01105650Phase 2Results posted
• First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube CancerCompletedNCT01097746Phase 2Results posted
• Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast CancerCompletedNCT01091428Phase 2Results posted
• Irinotecan and Bevacizumab for Recurrent Ovarian CancerCompletedNCT01091259Phase 2Results posted
• Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube CancerActive, not recruitingNCT01081262Phase 3Results posted
• Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological MalignanciesCompletedNCT01079832Phase 2Results posted
• Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal AdenocarcinomaTerminatedNCT01035658Phase 1/2Results posted
• Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube CancerCompletedNCT01031381Phase 2Results posted
• Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal CancerActive, not recruitingNCT01012817Phase 1/2Results posted
• Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell CancerCompletedNCT01010126Phase 2Results posted
• Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT01001910Phase 2Results posted
• Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian CancerCompletedNCT00993655Phase 2Results posted
• Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or CisplatinCompletedNCT00993616Phase 2Results posted
• Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity CancerStatus unknownNCT00954174Phase 3Results posted
• Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian CancerTerminatedNCT00910000Phase 1/2Results posted
• Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerTerminatedNCT00903630Phase 1/2Results posted
• A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian CancerCompletedNCT00880360Phase 2Results posted
• S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT00872989Phase 2Results posted
• Outcomes From Home in Patients Recovering From Major Gynecologic Cancer Surgery: Measuring Symptoms and Health-related Quality of LifeCompletedNCT00870233Results posted
• Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube CancerTerminatedNCT00866723Phase 2Results posted
• OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete RemissionCompletedNCT00857545Phase 2Results posted
• Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian MalignanciesCompletedNCT00856180Phase 2Results posted
• Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancersCompletedNCT00803569Phase 1Results posted
• Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and ImiquimodTerminatedNCT00799110Phase 2Results posted
• Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal CarcinomaCompletedNCT00768144Phase 2Results posted
• Study of Ramucirumab in Ovarian CancerCompletedNCT00721162Phase 2Results posted
• Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian CancerCompletedNCT00702299Phase 1Results posted
• A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal CancersCompletedNCT00698451Phase 2Results posted
• Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary AdenocarcinomaTerminatedNCT00653328Phase 2Results posted
• Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal CancerTerminatedNCT00652899Phase 2Results posted
• Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00617773Phase 2Results posted
• Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00616941Phase 1Results posted
• Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube CancerCompletedNCT00588237Phase 2Results posted
• Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal CarcinomaTerminatedNCT00582205Phase 2Results posted
• AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerTerminatedNCT00574951Phase 2Results posted
• Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube CancerCompletedNCT00569673Phase 2Results posted
• Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT00565851Phase 3Results posted
• Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)CompletedNCT00562640Phase 1Results posted
• Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00538031Phase 2Results posted
• Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second RemissionTerminatedNCT00522301Phase 2Results posted
• Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian TumorsCompletedNCT00520013Phase 2Results posted
• Letrozole in Patients With Ovarian TumorsTerminatedNCT00505661Phase 2Results posted
• Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum CarcinomaCompletedNCT00504257Phase 2Results posted
• Chemoimmunotherapy Study for Patients With Epithelial Ovarian CancerCompletedNCT00501644Phase 2Results posted
• Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous ChemotherapyCompletedNCT00466960Phase 2Results posted
• Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00459290Phase 2Results posted
• Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT00445549Phase 2Results posted
• VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerCompletedNCT00436501Phase 1/2Results posted
• Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal CancerCompletedNCT00436215Phase 2Results posted

← Fallopian Tube Neoplasms overview